Balanced news tone
News Sentiment
DXR sentiment intelligence
Daxor Corporation news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
News tone and price action are not far from neutral.
80/100 classification confidence.
directly relevant articles
high-authority source matches
+1.4% over one week, +13.7% over four weeks, trend inactive, and near fair-value range.
Daxor Corporation Announces First-Time Exhibition at the 14th Annual Dysautonomia International Conference in The Woodlands, Texas
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Daxor Corporation Announces First-Time Exhibition at the 14th Annual Dysautonomia International Conference in The Woodlands, Texas
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Jul 2026 15:36
- Source
- 富途牛牛
Daxor to exhibit blood volume analyzer at dysautonomia conference
Daxor Corporation announced its first-time exhibition at the 14th Annual Dysautonomia International Conference to showcase its FDA-cleared Blood Volume Analyzer (BVA). The company anticipates significant sales growth, with revenue projected to increase over 400% in fiscal 2026 du
- Tone
- Positive 72/100
- Event
- Earnings
- Published
- 08 Jul 2026 02:10
- Source
- Investing.com
Daxor debuts Blood Volume Analyzer at dysautonomia conference
Daxor Corporation (DXR) will exhibit its FDA-cleared, next-generation Blood Volume Analyzer (BVA) for the first time at the 14th Annual Dysautonomia International Conference in July 2026. The company aims to demonstrate how objective plasma and red blood cell volume data from the
- Tone
- Positive 70/100
- Event
- Market update
- Published
- 07 Jul 2026 12:10
- Source
- Stock Titan
DXR - Daxor Corp Forecast, Target Price
This article provides a detailed financial overview of Daxor Corp (DXR), including its last closing price, market capitalization, key financial ratios, and performance metrics. It lists various financial data points such as P/E, P/S, ROA, ROE, and percentage changes over differen
- Tone
- Positive 67/100
- Event
- Guidance
- Published
- 04 Jul 2026 12:39
- Source
- Finviz
DXR - Daxor Corp Earnings
This article provides a detailed financial overview of Daxor Corp (DXR), including key metrics such as market capitalization, P/E ratio, sales, and employee data. It also covers performance indicators like EPS growth, insider and institutional ownership, and various profitability
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 03 Jul 2026 05:10
- Source
- Finviz
DXR - Daxor Corp Options
This page provides a detailed financial overview of Daxor Corp (DXR), including its last closing price, market capitalization, income, sales, and various financial ratios. It also lists insider and institutional ownership, performance metrics over different periods, and analyst r
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 03 Jul 2026 00:40
- Source
- Finviz
Daxor Corporation (DXR) Edges Higher, Testing Key Resistance Zone - Advance Decline Volume
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 30 Jun 2026 17:48
- Source
- dars.gov.et
Daxor (DXR) CFO receives 12,000-share stock grant, now holds 33,050
Daxor Corp's CFO, Michel Robert J, received a compensation-related grant of 12,000 shares of Daxor Common Stock with no purchase price. These shares are scheduled to vest on June 23, 2026. Following this transaction, his direct holdings in the company's common stock total 33,050
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Jun 2026 10:10
- Source
- Stock Titan
Daxor (DXR) Chief Scientific Officer receives 25,000-share stock grant
Daxor's Chief Scientific Officer, Jonathan Adam Feldschuh, received a grant of 25,000 shares of Daxor common stock. This equity award, granted at $0.00 per share, increases his direct holdings to 78,908 shares. The granted shares are set to vest on June 23, 2026, indicating a com
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Jun 2026 00:10
- Source
- Stock Titan
Form 4 Daxor Corp For: 25 June By Investing.com
This article from Investing.com reports on a Form 4 filing for Daxor Corp, specifically for June 25th. The content is brief, primarily acting as a headline to direct readers to the filing details, and mentions the stock symbol DXR with a -2.91% performance. It also lists various
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 Jun 2026 23:14
- Source
- Investing.com South Africa
DAXOR (DXR) CEO receives 30,000-share equity grant, now holds 243,694
DAXOR CORP CEO Michael Richard Feldschuh was granted 30,000 shares of Daxor Common Stock as compensation, vesting on June 23, 2026. This transaction, reported on Form 4, increased his direct holdings to 243,694 shares, with the granted shares valued at $0.00 each. This equity awa
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 Jun 2026 23:09
- Source
- Stock Titan
Daxor (DXR) director awarded 2,500 stock options at $10.14 strike
Daxor Corp director Henry D. Cremisi was granted 2,500 stock options with an exercise price of $10.14 per share, expiring on June 23, 2031. This compensation award is contingent on SEC approval of an amendment to the Daxor Corporation 2020 Incentive Compensation Plan and will ves
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 25 Jun 2026 21:41
- Source
- Stock Titan
Daxor (DXR) director granted 2,500 stock options at $10.14
Daxor Corp director Joy S. Goudie was granted 2,500 stock options with an exercise price of $10.14 per share, expiring on June 23, 2031. The options will vest in three annual installments from June 23, 2026, to June 23, 2028. This grant is contingent on SEC approval of an amendme
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 25 Jun 2026 21:41
- Source
- Stock Titan
DAXOR CORP (DXR) director receives 2,500 stock options at $10.14 strike
DAXOR CORP director Edward Feuer was granted 2,500 stock options as compensation, with an exercise price of $10.14 per share and an expiration date of June 23, 2031. The grant is contingent on SEC approval to amend the Daxor Corporation 2020 Incentive Compensation Plan and will v
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 25 Jun 2026 20:41
- Source
- Stock Titan
DAXOR (DXR) director awarded 2,500 stock options at $10.14 strike price
DAXOR CORP director Caleb DesRosiers was granted 2,500 stock options with an exercise price of $10.14 per share, vesting in three annual installments through June 23, 2028. This grant is contingent on SEC approval of an amendment to the Daxor Corporation 2020 Incentive Compensati
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 25 Jun 2026 20:41
- Source
- Stock Titan
Daxor (NASDAQ: DXR) investors reelect full board and ratify Bush & Associates as auditor
Daxor Corporation (NASDAQ: DXR) shareholders reelected all six directors—Henry D. Cremisi, Edward Feuer, Joy Goudie, Michael Feldschuh, Jonathan Feldschuh, and Caleb DesRosiers—at their Annual Meeting held on June 23, 2026. Each director received robust support, with "for" votes
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 24 Jun 2026 20:40
- Source
- Stock Titan
Daxor Corporation (DXR) Holds Near Support After Modest Decline - Quality Factor
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 22 Jun 2026 07:00
- Source
- dars.gov.et
Daxor (DXR) Q4 2024 earnings summary
Daxor (DXR) reported a strong Q4 2024, with net assets rising to $36.8M and revenue up 116.5% year-over-year. The company achieved cash flow break-even in Q1 2025 and expanded clinical adoption, while also investing in R&D and manufacturing. Daxor anticipates significant growth f
- Tone
- Positive 73/100
- Event
- Earnings
- Published
- 19 Jun 2026 19:11
- Source
- Quartr
Daxor (DXR) Proxy Filing Summary
Daxor (DXR) has scheduled its annual meeting for July 15, 2024, where shareholders will vote on electing six directors and ratifying Citrin Cooperman, LLP as the independent auditor for 2024. The Board recommends approving all director nominees and the auditor. Shareholders of re
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 19 Jun 2026 19:11
- Source
- Quartr
Daxor (DXR) Q4 2025 earnings summary
Daxor (DXR) achieved a transformative 2025, marked by significant growth in its operating division and a substantial increase in total net assets to over $45.8 million, largely due to a strategic realignment and FDA 510(k) clearance for a new analyzer. The company saw a 45% year-
- Tone
- Positive 79/100
- Event
- Earnings
- Published
- 19 Jun 2026 18:40
- Source
- Quartr
Daxor (DXR) Q2 2024 earnings summary
Daxor (DXR) reported its Q2 2024 earnings, showing an increase in net assets year-over-year but a decrease from the end of 2023. The company experienced an improved net decrease in net assets from operations compared to the prior year, driven by higher sales of BVA system devices
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 19 Jun 2026 18:40
- Source
- Quartr
Daxor Corp (DXR) Dividends & Stock Splits: Historical Payouts and Event Timeline
This page provides historical dividend and stock split information for Daxor Corp (DXR). It indicates that Daxor Corp has distributed $0.00 in dividends over the past five years and currently shows no records of past stock splits. The page also includes current stock price data a
- Tone
- Neutral 50/100
- Event
- Capital return
- Published
- 18 Jun 2026 06:11
- Source
- TradingKey
Daxor Corp (DXR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article from TradingKey provides a revenue breakdown for Daxor Corp (DXR), detailing its business segments and regional revenue and profit contributions. It notes that relevant financial data for these categories has not yet been disclosed by the company. The page also offer
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 18 Jun 2026 05:40
- Source
- TradingKey
Daxor Corp (DXR) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Daxor Corp (DXR), listing major individual and institutional holders. It highlights that Joseph Feldschuh UEO is the largest shareholder with 43.82%, followed by other Feldschuh family members. The report also provides a breakdown
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 02:40
- Source
- TradingKey
Daxor Corp (DXR) Institutional Confidence
This article from TradingKey provides an overview of Daxor Corp's (DXR) institutional confidence, including its stock performance, key financial metrics, and a list of major shareholders. The data highlights significant institutional holdings and recent changes in shareholder act
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Jun 2026 09:10
- Source
- TradingKey
Daxor Corp (DXR) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Daxor Corp (DXR), based on analysis from TradingKey. It highlights a target price of USD 22.50 with a 142.98% upside potential, derived from 2 analysts who largely recommend a "Buy" rating for the stock. Key financial data such as ma
- Tone
- Positive 75/100
- Event
- Earnings
- Published
- 17 Jun 2026 08:10
- Source
- TradingKey
DXR - Daxor Corp Stock Price and Quote
Daxor Corp (DXR) is a company specializing in medical instruments and supplies, particularly known for its BVA-100 Blood Volume Analyzer. The article provides a detailed overview of the company's financial performance, recent news releases highlighting new patents, product adopti
- Tone
- Positive 80/100
- Event
- Market update
- Published
- 04 Jun 2026 14:40
- Source
- Finviz
Daxor Corporation Receives U.S. Patent for Breakthrough Remote Blood Volume Monitor
Daxor Corporation announced it has received a U.S. patent for a "Remote Blood Volume Monitor." This new technology allows for continuous, remote tracking of a patient's blood volume status using wearable sensors, such as smartwatches, complementing Daxor's existing baseline measu
- Tone
- Positive 90/100
- Event
- Market update
- Published
- 04 Jun 2026 02:39
- Source
- The Manila Times
Daxor (DXR) plans June 23, 2026 vote on directors and auditor
Daxor Corporation has scheduled its annual stockholder meeting for June 23, 2026, where shareholders will vote on electing six directors and ratifying Bush & Associates, CPA as the independent auditor for the 2026 fiscal year. The proxy statement details that as of May 20, 2026,
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 03 Jun 2026 20:39
- Source
- Stock Titan
Daxor (DXR) Secures Patent for Innovative Blood Volume Monitoring Technology
Daxor Corp (DXR) has secured a U.S. patent for an innovative system that enables remote monitoring of a patient's overall blood volume using non-invasive optical sensors, potentially integrated into wearable devices. This development is expected to improve patient care outcomes b
- Tone
- Positive 74/100
- Event
- Market update
- Published
- 03 Jun 2026 00:09
- Source
- GuruFocus